FibroGen Inc (FGEN)
1.165
+0.04
(+4.02%)
USD |
NASDAQ |
May 01, 16:00
1.165
0.00 (0.00%)
After-Hours: 17:51
FibroGen Enterprise Value: -11.06M for April 30, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 30, 2024 | -11.06M |
| April 29, 2024 | -14.02M |
| April 26, 2024 | -18.96M |
| April 25, 2024 | -20.94M |
| April 24, 2024 | -24.46M |
| April 23, 2024 | -16.00M |
| April 22, 2024 | -9.086M |
| April 19, 2024 | -8.098M |
| April 18, 2024 | -6.123M |
| April 17, 2024 | 3.754M |
| April 16, 2024 | 6.718M |
| April 15, 2024 | 7.705M |
| April 12, 2024 | 6.718M |
| April 11, 2024 | 12.64M |
| April 10, 2024 | 19.56M |
| April 09, 2024 | 27.46M |
| April 08, 2024 | 39.31M |
| April 05, 2024 | 38.32M |
| April 04, 2024 | 34.37M |
| April 03, 2024 | 23.51M |
| April 02, 2024 | 91.66M |
| April 01, 2024 | 111.42M |
| March 28, 2024 | 110.43M |
| March 27, 2024 | 133.14M |
| March 26, 2024 | 119.32M |
| Date | Value |
|---|---|
| March 25, 2024 | 139.07M |
| March 22, 2024 | 133.14M |
| March 21, 2024 | 118.33M |
| March 20, 2024 | 111.42M |
| March 19, 2024 | 110.43M |
| March 18, 2024 | 92.65M |
| March 15, 2024 | 84.75M |
| March 14, 2024 | 84.75M |
| March 13, 2024 | 75.86M |
| March 12, 2024 | 64.99M |
| March 11, 2024 | 47.21M |
| March 08, 2024 | 56.10M |
| March 07, 2024 | 55.12M |
| March 06, 2024 | 63.02M |
| March 05, 2024 | 68.94M |
| March 04, 2024 | 73.88M |
| March 01, 2024 | 59.07M |
| February 29, 2024 | 47.21M |
| February 28, 2024 | 74.38M |
| February 27, 2024 | 87.71M |
| February 26, 2024 | 61.04M |
| February 23, 2024 | 58.08M |
| February 22, 2024 | 64.99M |
| February 21, 2024 | 47.71M |
| February 20, 2024 | 56.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-145.12M
Minimum
Sep 22 2023
4.434B
Maximum
Feb 12 2021
1.637B
Average
1.356B
Median
Mar 23 2023
Enterprise Value Benchmarks
| Annovis Bio Inc | 55.58M |
| Emergent BioSolutions Inc | 846.64M |
| Geron Corp | 1.892B |
| Vertex Pharmaceuticals Inc | 90.24B |
| Regulus Therapeutics Inc | 128.14M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -56.23M |
| Revenue (Quarterly) | 27.14M |
| Total Expenses (Quarterly) | 81.33M |
| EPS Diluted (Quarterly) | -0.57 |
| Gross Profit Margin (Quarterly) | 80.08% |
| Profit Margin (Quarterly) | -207.2% |
| Earnings Yield | -251.5% |
| Normalized Earnings Yield | -242.80 |